A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region

K. Fizazi, M. Hussain, F. Saad, N. Shore, U. De Giorgi, E. Efstathiou, U. Ferreira, P. Ivashchenko, K. Madziarska, M. Al-Adhami, K. Modelska, D. Phung, J. Steinberg, C. N. Sternberg

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)viii277-viii278
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this